Sovaldi (Sofosbuvir) Patent Expiration, LOE Window & CMS Spending
Sovaldi (Sofosbuvir) by Gilead Sciences: FDA Orange Book core substance LOE 2031-06-11, 0 AB generics, $3.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N204671 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-06-11 |
| Last Listed Patent or Exclusivity Date | 2031-06-11 |
| Orange Book Patents (*PED Extensions) | 18 patents (9 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $3.5M |
| 2024 Medicare Part D Spend | $2.2M |
| 2024 Medicaid Spend | $1.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.